Hanmi Science Co Stock

Hanmi Science Co Current Liabilities

The Current Liabilities of Hanmi Science Co (008930.KS) as of Aug 8, 2026 is 468.83 B KRW. In the previous year, Current Liabilities was 395.20 B KRW — a change of 18.63% (higher).

Current Liabilities

468.83 BKRW

YoY

18.63%

Last updated:

Current Liabilities of Hanmi Science Co is 2026 468.83 B KRW. Current Liabilities of Hanmi Science Co was 2025 395.20 B KRW. It decreases by 18.63% higher compared to the previous year.
Access this data via the Eulerpool API

Hanmi Science Co Stock analysis

What does Hanmi Science Co do? Hanmi Science Co Ltd is a South Korean company specializing in the manufacturing of pharmaceutical products, biologics, and medical devices. The company was founded in 1973 as a chemical company and obtained the license for drug manufacturing in 1990, expanding its product range to include pharmaceuticals. Today, the company's business model includes three main areas: research and development, manufacturing and sales of drugs, and sales of medical devices. Hanmi aims to develop and produce innovative and high-quality products to improve people's health worldwide. In the field of research and development, Hanmi Science is a leading company. It specializes in the research and development of novel drugs and biologics. The company has an impressive track record in the development and marketing of innovative drugs for the treatment of diabetes, cancer, and rare diseases. This includes a range of biosimilars produced using biotechnological methods that are more affordable compared to original medical substances. Hanmi also has a state-of-the-art production infrastructure that meets the highest quality standards and ensures reliable supply. In the field of drug manufacturing, the company produces generics and biosimilars that are sold in more than 50 countries worldwide. Hanmi also specializes in the production of chemotherapeutics and parenteral drugs that have proven efficacy and safety. The medical device sales division focuses on marketing high-quality medical devices, including diagnostic and monitoring devices used in the medical field. Hanmi also distributes a range of medical consumables, including transfusion sets, syringes, infusion sets, and catheters. Hanmi Science Co Ltd offers a wide range of products that can be categorized into various categories. Among the pharmaceutical products are antidiabetic drugs, anticancer agents, antidepressants, antibiotics, antiviral medications, and products for the treatment of rare diseases. The portfolio also includes biosimilars of botulinum toxin, insulin, and humiderm among the biologics. Overall, Hanmi Science Co Ltd holds a strong position in the South Korean market and has also established a good reputation internationally. With its focus on research and development and the production of high-quality drugs and medical devices, the company has a promising future. Hanmi Science Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Hanmi Science Co stock

Current Liabilities of Hanmi Science Co is 468.83 B KRW in 2026.

Current Liabilities of Hanmi Science Co changed from 395.20 B KRW to 468.83 B KRW, representing a 18.63% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Current Liabilities Hanmi Science Co since 2006 – with annual values, charts, and detailed analysis.

Current liabilities are obligations due within one year, including accounts payable, short-term debt, and accrued expenses.

Current Liabilities's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Liabilities's Hanmi Science Co historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — Hanmi Science Co

All Key Metrics — Hanmi Science Co